Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation
Clinical trial NCT02001896 · UNKNOWN
Trial details
- NCT number
- NCT02001896
- Sponsor
- Xinjiang Medical University
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2015-06-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.